Emicizumab prophylaxis: Prospective longitudinal real-world follow-up and monitoring.

Assaf A BargIvan BudnikEinat AvishaiTami Brutman-BarazaniDalia BashariMudi MisgavAaron LubetskyAmir A KupermanTami Livnat Gili Kenet

Published in: Haemophilia : the official journal of the World Federation of Hemophilia (2021)

Emicizumab prophylaxis was mostly well tolerated, although 50% of patients experienced breakthrough bleeds. Routine TG monitoring is not obligatory, and further studies are warranted in selected patient populations.

Keyphrases

end stage renal disease
chronic kidney disease
newly diagnosed
peritoneal dialysis
prognostic factors
case report
clinical practice
cross sectional
patient reported outcomes